Quick Answer
BioCorRx Inc. reported Total Revenue of $797.2 thousand for the year ending 2025.
- BioCorRx Inc. showed an increase of +10,301.1% in Total Revenue from 2024 to 2025.
- This data is from BioCorRx Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $147.6 thousand | Q1 2018: $147.7 thousand | Q2 2018: $98.7 thousand | Q3 2018: $78.6 thousand | Q1 2019: $65.3 thousand | Q2 2019: $66.0 thousand | Q3 2019: $46.6 thousand | Q1 2020: $36.9 thousand | Q2 2020: $33.7 thousand | Q3 2020: $29.8 thousand | Q1 2021: $10.1 thousand | Q2 2021: $15.7 thousand | Q3 2021: $8.8 thousand | Q1 2022: $20.5 thousand | Q2 2022: $16.0 thousand | Q3 2022: $94.4 thousand | Q1 2023: $40.4 thousand | Q2 2023: $19.6 thousand | Q3 2023: $10.1 thousand | Q1 2024: $3.6 thousand | Q2 2024: $4.0 thousand | Q3 2024: $0.00 | Q1 2025: $134.9 thousand | Q2 2025: $178.2 thousand | Q3 2025: $635.2 thousand.
- Over the full 9 years of available data (2017 to 2025), BioCorRx Inc.'s Total Revenue has grown by 21.3%.
- Historical annual values: Fiscal year 2025: $797.2 thousand | Fiscal year 2024: $7.7 thousand | Fiscal year 2023: $89.2 thousand | Fiscal year 2022: $213.8 thousand | Fiscal year 2021: $48.3 thousand | Fiscal year 2020: $122.6 thousand | Fiscal year 2019: $240.3 thousand | Fiscal year 2018: $376.7 thousand | Fiscal year 2017: $657.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: